enVVeno Medical CorpNVNO
Price (close)
$9.09
Market cap
$6.1M
P/E
—
Revenue (TTM)
—
Net income
-$15.7M
Dividend yield
—
1-year total return
-72.9%
Net margin
—
Revenue growth
—
Debt / equity
—
What enVVeno Medical Corp does.
Medical Corporation is a medical device company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve
chronic disease, impacting approximately 70% of the adult population of the U.S. Chronic Venous Insufficiency (“CVI”), is
a large subset of CVD, which most often occurs when valves inside of the veins of the leg become damaged, resulting in the backwards
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Net income | -$9.1M | -$16.5M | -$24.7M | -$23.5M | -$21.8M | -$19.5M |
| Free cash flow | -$7.9M | -$12.2M | -$15.7M | -$18.9M | -$16.9M | -$15.6M |
More on NVNO.
- enVVeno Medical Corp summary
- enVVeno Medical Corp financial statements
- enVVeno Medical Corp key metrics
- enVVeno Medical Corp health scores and style box
- enVVeno Medical Corp earnings
- enVVeno Medical Corp dividends
- enVVeno Medical Corp valuation
- enVVeno Medical Corp ownership and insiders
- enVVeno Medical Corp peers
Figures from enVVeno Medical Corp's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.